巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2023-02-14
2021-11-24
2021-06-30
2023-03-10
2021-07-09
2022-01-06
2022-12-19
2022-02-10
2021-10-14
2023-06-25
2021-09-06
